| Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies E Molinaro, C Romei, A Biagini, E Sabini, L Agate, S Mazzeo, G Materazzi, ... Nature Reviews Endocrinology 13 (11), 644-660, 2017 | 428 | 2017 |
| Treatment of advanced thyroid cancer with targeted therapies: ten years of experience D Viola, L Valerio, E Molinaro, L Agate, V Bottici, A Biagini, L Lorusso, ... Endocrine-related cancer 23 (4), R185-R205, 2016 | 207 | 2016 |
| High serum cholesterol is a novel risk factor for Graves' orbitopathy: results of a cross-sectional study E Sabini, B Mazzi, MA Profilo, T Mautone, G Casini, R Rocchi, I Ionni, ... Thyroid 28 (3), 386-394, 2018 | 82 | 2018 |
| Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy GR Dottore, L Torregrossa, P Caturegli, I Ionni, A Sframeli, E Sabini, ... JAMA ophthalmology 136 (6), 613-619, 2018 | 71 | 2018 |
| Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study G Lanzolla, E Sabini, MA Profilo, B Mazzi, A Sframeli, R Rocchi, ... Journal of Endocrinological Investigation 41, 1417-1423, 2018 | 59 | 2018 |
| Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer L Lorusso, L Pieruzzi, A Biagini, E Sabini, L Valerio, C Giani, ... OncoTargets and therapy, 6467-6477, 2016 | 49 | 2016 |
| Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy M Marinò, G Rotondo Dottore, I Ionni, G Lanzolla, E Sabini, D Ricci, ... Journal of endocrinological investigation 42, 471-480, 2019 | 45 | 2019 |
| Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial G Lanzolla, E Sabini, M Leo, F Menconi, R Rocchi, A Sframeli, P Piaggi, ... The Lancet Diabetes & Endocrinology 9 (11), 733-742, 2021 | 43 | 2021 |
| Does Graves’ orbitopathy ever disappear answers to an old question E Sabini, M Leo, B Mazzi, R Rocchi, F Latrofa, M Nardi, P Vitti, C Marcocci, ... European thyroid journal 6 (5), 263-270, 2017 | 26 | 2017 |
| Natural history of Graves’ orbitopathy after treatment F Menconi, M Leo, E Sabini, T Mautone, M Nardi, A Sainato, ... Endocrine 57, 226-233, 2017 | 19 | 2017 |
| Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ disease: results of a pilot study G Lanzolla, D Ricci, F Nicolì, E Sabini, A Sframeli, A Brancatella, ... Journal of endocrinological investigation 43, 1759-1768, 2020 | 17 | 2020 |
| Variables affecting the long-term outcome of graves orbitopathy following high-dose intravenous glucocorticoid pulse therapy in patients not treated with orbital radiotherapy M Leo, T Mautone, I Ionni, MA Profilo, E Sabini, F Menconi, B Mazzi, ... Endocrine Practice 22 (10), 1177-1186, 2016 | 17 | 2016 |
| Pre-existing thyroid autoimmunity and risk of papillary thyroid cancer: a nested case-control study of US active-duty personnel DSA McLeod, SA Bedno, DS Cooper, SM Hutfless, S Ippolito, SJ Jordan, ... Journal of Clinical Oncology 40 (23), 2578-2587, 2022 | 16 | 2022 |
| A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab E Sabini, A Sframeli, M Marinò Journal of Endocrinological Investigation 41, 877-878, 2018 | 14 | 2018 |
| Pre-existing thyroiditis ameliorates papillary thyroid cancer: insights from a new mouse model F Pani, Y Yasuda, G Di Dalmazi, P Chalan, K Gabrielson, L Adamo, ... Endocrinology 162 (10), bqab144, 2021 | 13 | 2021 |
| Acromegaly in the setting of Tatton-Brown-Rahman syndrome C Hage, E Sabini, H Alsharhan, JA Fahrner, A Beckers, A Daly, ... Pituitary 23, 167-170, 2020 | 12 | 2020 |
| Oxidative phosphorylation in bone cells E Sabini, L Arboit, MP Khan, G Lanzolla, E Schipani Bone Reports 18, 101688, 2023 | 10 | 2023 |
| Distinct cytokine signatures in thyroiditis induced by PD-1 or CTLA-4 blockade: insights from a new mouse model S Ippolito, G Di Dalmazi, F Pani, E Sabini, P Caturegli Thyroid 31 (12), 1839-1849, 2021 | 10 | 2021 |
| Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves’ orbitopathy E Sabini, E Sisti, B Coco, M Leo, I Ionni, F Menconi, MA Profilo, B Mazzi, ... Journal of Endocrinological Investigation 39, 1323-1327, 2016 | 10 | 2016 |
| Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients M Leo, E Sabini, I Ionni, A Sframeli, B Mazzi, F Menconi, E Molinaro, ... Journal of endocrinological investigation 41, 357-361, 2018 | 9 | 2018 |
